Fluralaner 13.64% Chew Tablets

Verify with FDA CVM →

873 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
873
Total Reports
7
Deaths Reported
80.0%
Death Rate

Active Ingredients

Fluralaner 13.64% Chew Tablets

Administration Routes

OralUnknown

Species Affected

Dog 861
Unknown 10
Cat 2

Most Affected Breeds

Crossbred Canine/dog 227
Retriever - Labrador 74
Chihuahua 31
Retriever - Golden 29
Shepherd Dog - German 28
Pit Bull 28
Shih Tzu 27
Terrier - Yorkshire 23
Shepherd Dog - Australian 23
Terrier (unspecified) 20

Most Reported Reactions

Vomiting 311
Lack of efficacy (ectoparasite) - flea 141
Lack of efficacy (ectoparasite) - tick NOS 138
Emesis (multiple) 83
Lethargy (see also Central nervous system depression in 'Neurological') 76
Diarrhoea 51
Drug administration error 45
Product Defect, General 37
Product problem 33
UNPALATABLE 33
Lack of efficacy (bacteria) - NOS 27
Seizure NOS 27

Outcome Breakdown

Ongoing
432 (50.0%)
Recovered/Normal
408 (47.2%)
Outcome Unknown
15 (1.7%)
Euthanized
4 (0.5%)
Died
3 (0.3%)
Recovered with Sequela
2 (0.2%)

Data Summary

Metric Value
Total adverse event reports 873
Reports involving death 7
Case-fatality rate (reported events) 80.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Fluralaner 13.64% Chew Tablets Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 873 adverse event reports referencing Fluralaner 13.64% Chew Tablets, including 7 reports in which the animal died — a 80.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Fluralaner 13.64% Chew Tablets. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Fluralaner 13.64% Chew Tablets reports are Dog (861 reports), Unknown (10 reports), Cat (2 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (227), Retriever - Labrador (74), Chihuahua (31) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Fluralaner 13.64% Chew Tablets are Vomiting (311), Lack of efficacy (ectoparasite) - flea (141), Lack of efficacy (ectoparasite) - tick NOS (138), Emesis (multiple) (83). Of the 864 reports with a coded outcome, Ongoing is the leading category at 50.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Fluralaner 13.64% Chew Tablets.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial